Literature DB >> 32638251

Impact of the longitudinal quantitative assessment of juvenile systemic lupus erythematosus severity on the disease outcome.

Maria Trachana1, Polyxeni Pratsidou-Gertsi2, Florence Kanakoudi-Tsakalidou2, Vasiliki Tzimouli2, Nikoleta Printza3, Fotis Papachristou3.   

Abstract

OBJECTIVES: This study on juvenile SLE patients aimed to evaluate retrospectively the impact of a tertiary center's management policy of the disease severity on its long-term progression and cumulative damage development as well as provision of quality-driven medical care (QmC).
METHODS: Disease activity was assessed by the Physician Global Assessment and SLEDAI-2K, flares by SELENA/SLEDAI, and damage by the pediatric SLICC/DI at diagnosis, 6 months post-diagnosis, and annually thereafter. At the same time, QmC was evaluated by relevant indices and quality of life was captured by the Greek version of the General Health Questionnaire only at the last visit.
RESULTS: A total of 35 patients (25/35 females) aged at diagnosis 5.5-15.16 years (median 11.83) with a median lag time to diagnosis 1.8 months had a follow-up of 5 (35/35) and 10 years (13/35), respectively. The predominant baseline manifestations were consistent with those previously reported. Out of 35 patients, 24 (68.5%) were clinically inactive at year 5, and 5/13 (38%) at year 10. All patients received immunosuppressives and 7/35 biologics in addition. At the end of their follow-up, damage was found in 9/35 patients, but none of them had a neuropsychiatric disorder. Over the study, 28/35 patients were compliant with the QmC recommendations.
CONCLUSIONS: An early diagnosis combined with a longitudinal quantitative assessment of the disease activity and severity contributes to the continuous evaluation of the disease state. They are the key determinants for the selection of an early, targeted, and personalized management; they restrict the cumulative damage development and contribute to an optimal outcome. Key Points • Juvenile SLE has a heavier introductory profile than in adults and an unpredictable trajectory. • The application of contemporary metric tools for assessing the disease state leads to an objective assessment and regimen selection. • An early diagnosis combined with longitudinal quantitative assessment is a key determinant for an optimal management and a minimal damage development.

Entities:  

Keywords:  Childhood-onset SLE; Pediatric SLE; jSLE clinimetric tools; jSLE outcome; jSLE quality-driven care; jSLE trajectory assessment

Mesh:

Substances:

Year:  2020        PMID: 32638251     DOI: 10.1007/s10067-020-05252-8

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  7 in total

Review 1.  Assessment of systemic lupus erythematosus.

Authors:  G K W Lam; M Petri
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

Review 2.  Childhood-Onset Systemic Lupus Erythematosus: A Review and Update.

Authors:  Onengiya Harry; Shima Yasin; Hermine Brunner
Journal:  J Pediatr       Date:  2018-05       Impact factor: 4.406

3.  Validity and reliability of lupus activity measures in the routine clinic setting.

Authors:  M Petri; D Hellmann; M Hochberg
Journal:  J Rheumatol       Date:  1992-01       Impact factor: 4.666

Review 4.  Systemic lupus erythematosus diagnosis and management.

Authors:  Bernard Thong; Nancy J Olsen
Journal:  Rheumatology (Oxford)       Date:  2017-04-01       Impact factor: 7.580

5.  Systemic lupus erythematosus disease activity index 2000.

Authors:  Dafna D Gladman; Dominique Ibañez; Murray B Urowitz
Journal:  J Rheumatol       Date:  2002-02       Impact factor: 4.666

6.  Damage accumulation in systemic lupus erythematosus and its relation to disease activity and mortality.

Authors:  Andrea Becker-Merok; Hans C Nossent
Journal:  J Rheumatol       Date:  2006-08       Impact factor: 4.666

7.  Pediatric Systemic Lupus Erythematosus: Learning From Longer Follow Up to Adulthood.

Authors:  Giorgio Costagliola; Marta Mosca; Paola Migliorini; Rita Consolini
Journal:  Front Pediatr       Date:  2018-05-16       Impact factor: 3.418

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.